



Xellia Pharmaceuticals welcomes HRH Princess Benedikte of Denmark to its Copenhagen Site

- *Visit in recognition of Xellia's long-term commitment to SOS Children's Villages of which HRH Princess Benedikte is a Patron*

Copenhagen, Denmark, 14th January 2019 - Xellia Pharmaceuticals ('Xellia' or the 'Company'), an international specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, announces that HRH Princess Benedikte of Denmark today visited its headquarters and production site in Copenhagen in her role as a Patron of SOS Children's Villages.

Xellia has supported SOS Children's Villages as its Company charity of choice since 2005, becoming a long term partner to the non-political, non-religious, social development organization, which promotes the rights of children in over 130 counties and territories around the world. The charity provides over 2 million children and their families with a safe place to live, learn and grow up.

HRH Princess Benedikte was welcomed by Xellia's CEO, Carl-Åke Carlsson, and discussed the types of activities that Xellia has sponsored, including the Company's support for a SOS Medical Center in Eldoret, Kenya. Xellia's support from 2015-2017 has enabled it to expand several of its diagnostic and clinical services such that the Center is now self-sufficient and can provide free medical services to those in need. Xellia has now pledged finances, from 2018-2020 to support the SOS' Family Strengthening Program in Eldoret, Kenya, which aims to alleviate hardship in the local community so that family stability can be maintained and children will not be abandoned.

Commenting on the visit, Carl-Åke Carlsson, CEO Xellia said:

"It was an immense honour to be able to welcome Her Royal Highness Princess Benedikte on her visit. As a Company we are driven to support people in need.

Xellia's support goes well beyond the corporate level, with our employees from many of our global offices independently volunteering to raise additional funds to support local SOS Children's Villages projects and additional projects coordinated by SOS Children's Villages in Eldoret, Kenya. It has been fantastic to see staff personally engaging in this great cause, and connecting and uniting across geographies and departments to help improve the lives of children around the world."

HRH Princess Benedikte toured Xellia's Copenhagen site which has recently undergone a large expansion and upgrade of its sterile manufacturing facilities. During the tour she spoke with members of the Xellia production team and discussed the important role that Xellia is playing in the fight against infectious diseases. The Company has a strong heritage in the development, manufacture and supply of

several important established anti-infective drugs to over 500 pharmaceutical customers. With a focus on further building a sustainable global business, in 2014 Xellia started to generate an innovative pipeline of value-added anti-infective medicines, which it is launching and selling under its own label to the US hospital markets. These medicines are intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

Instinctif Partners (International media relations)

Eileen Paul / Rozi Morris / Melanie Toyne-Sewell

Tel: +44 (0) 20 7457 2020

Email: xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals ("Xellia") is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 100 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company's evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease-of-use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,500 people.

Further information about Xellia can be found at: www.xellia.com.